Stocks rose sharply on Thursday after the Federal Reserve hinted at possible interest rate cuts as soon as next month.US Marketsread more
The billionaire investor believes the stock market is in a "zone of fair value" at current levels.Marketsread more
The Federal Reserve may be on its way to delivering a half-point interest rate cut next month, according to Goldman Sachs economists.Economyread more
However, Slack chief Stewart Butterfield says, "The broader world of email will stick around."Technologyread more
Crude oil prices jump on news of the attack, which Iran says happened over its territory.World Politicsread more
Apple is considering moving some production from China as it is expected release of its new iPhone line this fall, The Wall Street Journal reported.Technologyread more
Workplace messaging firm Slack is about to go public in a red-hot IPO market, but it's approach to going public--using a "direct listing"--is slightly different than an IPO.Trader Talk with Bob Pisaniread more
The yield on the benchmark 10-year Treasury note fell below 2% for the first time since November 2016 on Wednesday.Bondsread more
National Securities' Art Hogan sees the U.S.-China trade war as the market's biggest risk – not Fed policy.Trading Nationread more
The Philadelphia Federal Reserve's manufacturing gauge tumbled this month, solidifying the Fed's case for easier monetary policy.Economyread more
Declining traffic to Olive Garden, Darden's top restaurant chain, resulted in weaker-than-expected revenue for its fiscal fourth quarter.Restaurantsread more
Abbott is taking its partnership with a diabetes care start-up one step further.
The health-care company hsa invested an undisclosed amount in Bigfoot Biomedical, a start-up creating diabetes care devices and systems. Bigfoot said Wednesday it has raised $55 million in Series B financing, bringing its total funding to $90 million.
The funds will help Bigfoot build a diabetes platform that will offer everything but the insulin, said CEO Jeffrey Brewer. Bigfoot plans to develop insulin pens, pumps and glucose monitors and connect them with smartphone technology. It also plans to prescribe them together and have them reimbursed as a monthly fee.
Abbott and Bigfoot previously agreed to integrate Abbott's new continuous glucose monitor, FreeStyle Libre, with Bigfoot's insulin delivery systems. Both companies want to automate what can be a challenging, time-consuming and dangerous process.
Abbott's FreeStyle Libre measures people's blood sugar automatically every 15 minutes for up to 10 days. Unlike most devices on the market, Libre doesn't require patients to prick their fingers and draw blood to keep it accurate.
Abbott and Bigfoot share a vision to create easy-to-use devices that are connected to smartphones and are accessible to as many people as possible, Brewer said. Part of Bigfoot's plan includes making it easier for doctors to write — and patients to manage — prescriptions.
"These are values and aspirations that both Abbott and Bigfoot share, so I think that makes us great partners," he said. "This investment on top of the existing supply agreement for the Libre to become part of the Bigfoot system, I think, just reinforces that we see the world in the same way."
Originally named SmartLoop Labs, Bigfoot was created in 2014 after co-founder and now Chief Product Officer Bryan Mazlish hacked and automated his son's insulin pump. The goal was to create a system that measures glucose levels and adjusts insulin levels on its own — a long-sought after goal in diabetes management.
Nearly four years later, the company is focused on building. It's about halfway to the amount it needs to finish, so Brewer said Bigfoot will start fundraising again next year. It also plans to start clinical trials with the hope of selling and marketing its systems in 2020.